Biopharma Leaders to Discuss Growing Importance of Drug Repositioning at Arrowhe ad's 2nd Annual Drug Repositioning Conference The

2nd Annual Drug Repositioning and Indications Discovery Conference is being held on October 23-24, 2012 in San Francisco, CA. This conference will feature a variety of speakers from academia, industry, non-profits and government. Their perspectives will provide insight into the field of drug repositioning and the c hallenges and successes in getting a repositioned drug to the marketplace. Minneapolis, MN, September 28, 2012 -- The 2nd Annual Drug Repositioning and Ind ications Discovery Conference is being held on October 23-24, 2012 in San Franci sco, CA. This conference will feature a variety of speakers from academia, indus try, non-profits and government. Their perspectives will provide insight into th e field of drug repositioning and the challenges and successes in getting a repo sitioned drug to the marketplace. Building on last year s conference, the 2nd Annual Drug Repositioning and Indications Discovery Conference will cover what has cha nged in the last year and what continues to drive interest in drug repositioning . Since the development of new drugs can be time consuming and expensive, drug rep ositioning has emerged as a potentially cost-effective and quicker alternative t o provide new drugs for pharmaceutical companies waning pipelines. With new technol ogies and approaches, drug repositioning has become more streamlined and less ac cidental than it was in the past. By using a more systematic approach, existing compounds are being tested for both common and neglected diseases faster and wit h more success. Speakers and panelists will focus on the following key themes: Market potential of drug repositioning Regulatory issues/timelines and legal frameworks for drug repositioning Drug Repositioning for neglected diseases Computational approaches to drug repositioning Technical innovations & challenges of drug repositioning Dr. Aris Persidis, President and Co-Founder, Biovista Inc. will discuss using sy stematic drug repositioning to map drugs and diseases against each other. He wil l provide case studies in both rare and mainstream diseases, including multiple sclerosis and Friedreich s ataxia. Dr. Barry Bunin, CEO and President, Collaborative Drug Discovery, will chair an exciting panel session entitled A New Era for Drug Repositioning: How Successes and Partnerships are Changing the Drug Development Process. Panel members includ e Dr. Christine Colvis, Program Officer, National Institutes of Health, National Center for Advancing Translational Sciences (NCATS), Dr. David Cavalla, Founder , Numedicus Ltd., and Dr. Christopher Lipinski, Scientific Advisor, Melior Disco very. Sasha K. Richardson, Vice President, GfK Bridgehead will share insight into pric ing, reimbursement, access challenges and opportunities for repositioning therap ies from both an EU and US payer perspective. Her presentation will be a mix of historic pitfalls/successes and forward thinking strategies to help navigate the cost constrained environment for reimbursing repositioned therapies. Numerous other speakers will be participating. Please visit www.drugrepositionin gconference.com to view the full agenda and information on how to register to at tend. Contact: John Waslif Arrowhead Publishers & Conferences

5412 Irving Ave S Minneapolis, MN 55419 312-244-3703 john.waslif@arrowheadpublishers.com http://www.arrowheadpublishers.co/